Rigel Pharmaceuticals, Inc.
350 articles with Rigel Pharmaceuticals, Inc.
-
When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.
-
Rigel Pharmaceuticals reported a developmental setback for Tavalisse in a mid-stage kidney disease trial. Investors began dumping shares and the stock was down nearly 10 percent.
-
Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
4/3/2018
Company to host a conference call today at 8:00AM EDT to Discuss the Study Results
-
Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
3/6/2018
Rigel Pharmaceuticals, Inc. reported financial results for the fourth quarter and year end 2017.
-
Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
3/1/2018
Fostamatinib disodium is an oral investigational drug candidate designed to inhibit spleen tyrosine kinase, a key signaling component of the body's immune process that leads to platelet destruction in ITP and red blood cell destruction in AIHA.
-
Rigel Pharma, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
1/30/2018
Rigel Pharma today announced that on January 15, 2018 and January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 48,000 shares of common stock to three new employees.
-
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17.
-
More excitement should lie ahead for these small-cap biotechs this year.
-
Rigel Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
1/8/2018
Rigel Pharma today announced that on December 23, 2017 and January 2, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 200,000 shares of common stock to twelve new employees.
-
Nelson Cabatuan, Rigel's vice president, finance will serve as the company's interim principal accounting officer.
-
Rigel Pharma Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
12/11/2017
Rigel today announced that on December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee.
-
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 ASH Annual Meeting
12/8/2017
Rigel Pharma today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 ASH Annual Meeting.
-
Rigel Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/20/2017
These awards were granted pursuant to the Rigel PharmaInducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
11/8/2017
For the third quarter of 2017, Rigel reported a net loss of $17.7M, or $0.14 per basic and diluted share, compared to a net loss of $22.6M, or $0.24 per basic and diluted share, in the same period of 2016.
-
Rigel Welcomes Gregg Lapointe to Board of Directors
11/2/2017
Currently the CEO and co-founder of Cerium Pharma, Mr. Lapointe offers Rigel's board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases.
-
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results
10/31/2017
Rigel today announced that it will report its third quarter financial results after market close on Tuesday, November 7, 2017.
-
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
10/11/2017
-
Rigel Announces Pricing Of Public Offering Of Common Stock
10/5/2017
-
Rigel Announces Proposed Public Offering Of Common Stock
10/4/2017
-
Rigel Release: Fostamatinib Meets Pre-Specified Primary Endpoint In Stage 1 Of Autoimmune Hemolytic Anemia (AIHA) Phase II Study
10/3/2017